flavoxate has been researched along with Prostatic Hyperplasia in 2 studies
Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.
flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effectiveness of supplemental administration of flavoxate hydrochloride in patients with benign prostatic hyperplasia (BPH) whose nocturia was not adequately relieved by an alpha1-adrenoceptor blocker." | 7.74 | [Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker]. ( Asano, H; Hoshinaga, K; Izumitani, M; Kato, S; Kusaka, M; Ooki, T; Shiroki, R; Yanaoka, M, 2008) |
| "We examined the effectiveness of supplemental administration of flavoxate hydrochloride in patients with benign prostatic hyperplasia (BPH) whose nocturia was not adequately relieved by an alpha1-adrenoceptor blocker." | 3.74 | [Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker]. ( Asano, H; Hoshinaga, K; Izumitani, M; Kato, S; Kusaka, M; Ooki, T; Shiroki, R; Yanaoka, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, S | 1 |
| Kusaka, M | 1 |
| Shiroki, R | 1 |
| Izumitani, M | 1 |
| Asano, H | 1 |
| Ooki, T | 1 |
| Yanaoka, M | 1 |
| Hoshinaga, K | 1 |
| Dahm, TL | 1 |
| Ostri, P | 1 |
| Kristensen, JK | 1 |
| Walter, S | 1 |
| Frimodt-Møller, C | 1 |
| Rasmussen, RB | 1 |
| Nøhr, M | 1 |
| Alexander, N | 1 |
1 trial available for flavoxate and Prostatic Hyperplasia
| Article | Year |
|---|---|
Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Flavoxate; Humans; Male; Middle Aged; Parasympatholyti | 1995 |
1 other study available for flavoxate and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker].
Topics: Aged; Aged, 80 and over; Drug Resistance; Drug Therapy, Combination; Flavoxate; Humans; Male; Middle | 2008 |